Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Success in therapy for adults with acute lymphoblastic leukemia (ALL) has lagged behind that of children with ALL. However, the application of pediatric-intensive regimens to young and middle-aged adults suggests improved outcomes without excessive toxicity. A promising area in the treatment of adult ALL is the addition of monoclonal antibodies in various forms to chemotherapy in adults with ALL. New chemotherapeutic approaches show promise, and early-phase clinical trials with these drugs are under way.

Original languageEnglish (US)
Pages (from-to)1303-1317
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume25
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Monoclonal Antibodies
Clinical Trials
Pediatrics
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Acute lymphoblastic leukemia
  • Chemotherapy
  • Kinase inhibitor therapy
  • Monoclonal antibody therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia. / Litzow, Mark R.

In: Hematology/Oncology Clinics of North America, Vol. 25, No. 6, 12.2011, p. 1303-1317.

Research output: Contribution to journalReview article

@article{636cde15fcb54b869b4fcf6b8cca3d0d,
title = "Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia",
abstract = "Success in therapy for adults with acute lymphoblastic leukemia (ALL) has lagged behind that of children with ALL. However, the application of pediatric-intensive regimens to young and middle-aged adults suggests improved outcomes without excessive toxicity. A promising area in the treatment of adult ALL is the addition of monoclonal antibodies in various forms to chemotherapy in adults with ALL. New chemotherapeutic approaches show promise, and early-phase clinical trials with these drugs are under way.",
keywords = "Acute lymphoblastic leukemia, Chemotherapy, Kinase inhibitor therapy, Monoclonal antibody therapy",
author = "Litzow, {Mark R}",
year = "2011",
month = "12",
doi = "10.1016/j.hoc.2011.09.019",
language = "English (US)",
volume = "25",
pages = "1303--1317",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia

AU - Litzow, Mark R

PY - 2011/12

Y1 - 2011/12

N2 - Success in therapy for adults with acute lymphoblastic leukemia (ALL) has lagged behind that of children with ALL. However, the application of pediatric-intensive regimens to young and middle-aged adults suggests improved outcomes without excessive toxicity. A promising area in the treatment of adult ALL is the addition of monoclonal antibodies in various forms to chemotherapy in adults with ALL. New chemotherapeutic approaches show promise, and early-phase clinical trials with these drugs are under way.

AB - Success in therapy for adults with acute lymphoblastic leukemia (ALL) has lagged behind that of children with ALL. However, the application of pediatric-intensive regimens to young and middle-aged adults suggests improved outcomes without excessive toxicity. A promising area in the treatment of adult ALL is the addition of monoclonal antibodies in various forms to chemotherapy in adults with ALL. New chemotherapeutic approaches show promise, and early-phase clinical trials with these drugs are under way.

KW - Acute lymphoblastic leukemia

KW - Chemotherapy

KW - Kinase inhibitor therapy

KW - Monoclonal antibody therapy

UR - http://www.scopus.com/inward/record.url?scp=81255177073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255177073&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.09.019

DO - 10.1016/j.hoc.2011.09.019

M3 - Review article

C2 - 22093588

AN - SCOPUS:81255177073

VL - 25

SP - 1303

EP - 1317

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -